Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide

Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide

Tacrolimus (Tac) is a pivotal immunosuppressant agent used to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloHSCT). Tac is characterized by a narrow therapeutic window and a high inter-patient and intra-patient pharmacokinetic variability (IPV). Although hig...

Full description

Bibliographic Details
Main Authors: Daniel N. Marco, María Queralt Salas, Gonzalo Gutiérrez-García, Inés Monge, Gisela Riu, Esther Carcelero, Joan Ramón Roma, Noemí Llobet, Jordi Arcarons, María Suárez-Lledó, Nuria Martínez, Alexandra Pedraza, Ariadna Domenech, Laura Rosiñol, Francesc Fernández-Avilés, Álvaro Urbano-Ispízua, Montserrat Rovira, Mercè Brunet, Carmen Martínez
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Pharmaceuticals
Subjects:
tacrolimus
therapeutic drug monitoring
graft-versus-host disease
tacrolimus intra-patient variability
allogeneic stem cell transplantation
post-transplant cyclophosphamide
Online Access:https://www.mdpi.com/1424-8247/15/12/1529

Internet

https://www.mdpi.com/1424-8247/15/12/1529

Similar Items